

Press release for immediate release

## **Genomtec continues to add distributors for its flagship Genomtec®ID platform product and genetic respiratory tests in Europe**

**Wrocław, Poland - June 27, 2022. - Genomtec S.A. "GMT", a NewConnect-listed MedTech company specializing in the development of advanced technology in the area of point-of-care (POCT) genetic diagnostics, has secured an additional distributor for its Genomtec®ID portable testing platform and RP5-PLEX panel for detecting respiratory tract infections in Europe by entering into an agreement with ForLab SA. Forlab is the second distributor of the Company's flagship platform after the Greek company Atropos. ForLab has become Genomtec's exclusive sales partner in Belgium, the Netherlands and Luxembourg. The company has recently obtained CE-IVD certification, allowing it to sell its newly registered solution in 27 countries of the European Union as well as in Iceland, Norway and Liechtenstein.**

Under the agreement, Forlab will be responsible for market penetration, sales support, and product promotion in the BeNeLux region. Minimum purchase values for the Genomtec®ID analyzers and reaction cards will be reviewed on an annual basis.

ForLab SA specializes in importing and distributing clinical diagnostic products and laboratory equipment and reagents from around the world to Belgium, the Netherlands and Luxembourg. The company was founded in 1982 and is headquartered in Brussels. The Contractor's customers are primarily academic laboratories and hospitals as well as smaller medical and general entities such as universities, institutes, government laboratories, contract research organizations, pharmaceutical and biotechnology companies.

*- I am delighted with the market interest in our breakthrough solution and the addition of ForLab to our distribution family. They are a very valuable partner with extensive contacts in Belgium, the Netherlands and Luxembourg which will help us get early adopters in the European marketplace. Obtaining CE-IVD certification will be helpful in securing more commercial partners in additional countries, which we look forward to – said Charudutt Shah, Chief Business Officer in Genomtec.*

On June 8, 2022, Genomtec announced obtaining the CE-IVD mark for its flagship solution, the Genomtec®ID Respiratory Panel 5-Plex (RP5-PLEX). It is the only diagnostic panel of its kind to simultaneously test for the presence of up to 5 viruses and bacteria in the same test available in Europe. The Genomtec®ID RP5-PLEX panel detects Influenza A and B viruses, RSV (Respiratory Syncytial Virus), SARS-CoV-2 and the atypical bacteria *Mycoplasma pneumoniae* and *Chlamydomphila pneumoniae*. The Genomtec®ID analyzer, into which a reaction card (panel) is inserted along with a patient sample for genetic testing, is one of the smallest portable genetic testing instrument in the world.

#####

## **Additional information at:**

Genomtec S.A.

Magdalena Kicińska

+48 604 201 230

[m.kicinska@genomtec.com](mailto:m.kicinska@genomtec.com)

## **About Genomtec:**

Genomtec is an innovative medical technology company engaged in the development and commercialization of a mobile platform used in molecular clinical diagnostics of, among others, a number of infectious diseases, including rapid diagnostic tests applicable, among others, in the detection of COVID-19 disease caused by SARS-CoV-2 virus.

The company's flagship project is the Genomtec ID mobile genetic diagnostic system. The analyzer is a unique solution in the world in this type of equipment. It will allow for fast and precise molecular analysis outside the laboratory environment and without the need to involve qualified laboratory staff. The system utilizes microfluidic technology and proprietary, patented SNAAT® isothermal technology. Proper design of the system enables the process to be performed in a short 35-45 minutes, with efficiencies equal to, and in some cases exceeding, the quality of laboratory PCR assays.

On June 8, 2022, Genomtec announced obtaining CE-IVD certification for the Genomtec®ID RP5-PLEX diagnostic panel, which simultaneously detects the presence of influenza A and B viruses, Respiratory Syncytial Virus (RSV), SARS-CoV-2, and the atypical bacteria *Mycoplasma pneumoniae* and *Chlamydomphila pneumoniae*. The Genomtec®ID analyzer, into which a reaction card (panel) is inserted along with a patient sample for genetic testing, is one of the smallest portable genetic laboratories in the world.

The development and production process is carried out in close cooperation with international CMO (Contract Manufacturing Organization) companies. The commercialization of the flagship solution took place in the first half of 2022.

Genomtec was founded in 2016. The headquarters of Genomtec SA is located in Wrocław, Poland.

For more information: [www.genomtec.com](http://www.genomtec.com)